宜明昂科-B(01541)收到AXION BIO的授权及合作协议项下里程碑付款

Group 1 - The core point of the article is that Yiming Anke-B (01541) has received FDA approval to initiate Phase I clinical trials for IMM2510/AXN-2510 in the United States, leading to a milestone payment of 10 million USD from Instil [1] - As of the date of the announcement, the total payments received under the authorization and collaboration agreement have reached 30 million USD, including milestone payments, indicating ongoing progress and commitment between the company and Instil [1]